Oncogene 1999, 18: 2281–2290.CrossRefPubMed 26. Durie BGM, Salmon SE: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with

presenting clinical features, response to treatment, and survival. Cancer 1975, 36: 842–847.CrossRefPubMed 27. Kahn SM, Jang W, Culbertson TA, Weinstein IB, Williams GM, Tomita buy CX-4945 N, Ronai Z: Rapid and sensitive nonradioactive detection of mutant K- ras genes via “”enriched”" PCR amplification. Oncogene 1991, 6: 1079–1083.PubMed 28. Greco C, Cosimelli M, Vona R, Cosimelli M, Matarrese P, Straface E, Scordati P, Giannarelli D, Casale V, Assisi D, Mottolese M, Moles A, Malorni W: Cell surface overexpression of Galectin-3 and the presence of its

ligand 90 k in the blood plasma as determinants of colon neoplastic lesions. Glycobiol 2004, 14: 783–792.CrossRef learn more 29. Bezieau S, ARS-1620 concentration Devilder MC, Avet-Loiseau H, Mellerin MP, Puthier D, Pennarun E, Rapp MJ, Harousseau JL, Moisan JP, Bataille R: High incidence of N and K- Ras activating utations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat 2001, 18: 212–224.CrossRefPubMed 30. Hu L, Shi Y, Hsu J, Gera J, Van Ness B, Lichtenstein A: Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 2003, 101: 3126–3135.CrossRefPubMed 31. Jakob C, Sterz J, Zavrski I, Heider U, Kleeberg L, Fleissner C, Kaiser M, Sezer O: Angiogenesis in multiple myeloma. Eur J Cancer 2006, 42: 1581–1590.CrossRefPubMed 32. Ria R, Vacca A, Russo F, Cirulli T,

Massaia M, Tosi P, Cavo M, Guidolin D, Ribatti D, Dammacco F: VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. Thromb Haemost 2005, 92 (6) : 1438–1445. 33. Alexandrakis ALOX15 MG, Passam FH, Boula A, Christophoridou A, Aloizos G, Roussou P, Kyriakou DS: Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basis fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Ann Hematol 2003, 82: 19–23.PubMed 34. Hatjiharissi E, Terpos E, Papaioannou M, Hatjileontis C, Kaloutsi V, Galaktidou G, Gerotziafas G, Christakis J, Zervas K: The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma. Hematol Oncol 2004, 22: 159–168.CrossRefPubMed 35. Alexandrakis MG, Passam FH, Sfiridaki A, Pappa CA, Moschandrea JA, Kandidakis E, Tsirakis G, Kyriakou DS: Serum levels of leptin in multiple myeloma patients and its relation to angiogenic and inflammatory cytokines. Int J Biol Markers 2004, 19 (1) : 52–57.PubMed 36. Cohen P: Overview of the IGF-I system. Horm Res 2006, 65: 3–8.